Adjuvant Tebentafusp in High Risk Ocular Melanoma
Conditions
Uveal Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Northwell Health -Center for Advanced Medicine, Lake Success, New York, United States
Cliniques Universitaires Saint-Luc, Brussels, Belgium
Centre Antoine Lacassagne, Nice, France
Institut Curie - Hôpital de Paris, Paris, France
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf KE - University Cancer Center, Hamburg, Germany
Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik, Heidelberg, Germany
Leiden University Medical Centre, Leiden, Netherlands
Erasmus MC, Rotterdam, Netherlands
Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), L'Hospitalet de Llobregat, Spain
Hospital Clinico Universitario De Valladolid, Valladolid, Spain
Sahlgrenska Universitetssjukhuset, Gothenburg, Sweden
The Clatterbridge cancer Center NHS foundation Trust - Clatterbridge Cancer Center - Liverpool, Liverpool, United Kingdom
East and North Hertfordshire NHS Trust - Mount Vernon Hospital, Northwood, United Kingdom
Study leads
Paul Nathan
Principal Investigator
Mount Vernon Cancer Centre, Northwood, UK
Richard D. Carvajal
Principal Investigator
Northwell Health Cancer Institute, NY, USA
Serge Leyvraz
Principal Investigator
Charité Hospital, Berlin, Germany